George et al. found that less than half of the real-world patients would have passed the angiographic eligibility criteria used in the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) and ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) studies. The gene discussed is VEGFA; the disease is choroidal neovascularization.